|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Impaired ß-Cell Function, Incretin Effect, and Glucagon Suppression in Patients With Type 1 Diabetes Who Have Normal Fasting Glucose
1 Benaroya Research Institute at Virginia Mason Research Center, Seattle, Washington
2 Department of Veterans Affairs, Puget Sound Health Care System, Seattle Division, and the University of Washington, Seattle, Washington
3 Department of Medicine, University of Cincinnati, Cincinnati, Ohio
We have recently described a novel phenotype in a group of subjects with type 1 diabetes that is manifested by glucose >11.1 mmol/l 120 min after an oral glucose load, but with normal fasting glucose levels. We now describe the metabolic characteristics of these subjects by comparing parameters of islet hormone secretion and glucose disposal in these subjects to age-matched nondiabetic control subjects. The patients with type 1 diabetes had fasting glucose, insulin, and glucagon values similar to those of control subjects. Additionally, the insulin secretory response to intravenous arginine at euglycemia was similar in the control and diabetic groups (264 ± 33.5 and 193 ± 61.3 pmol/l; P = 0.3). However, marked differences in ß-cell function were found in response to hyperglycemia. Specifically, the first-phase insulin response was lower in diabetic subjects (329.1 ± 39.6 vs. 91.3 ± 34.1 pmol/l; P < 0.001), as was the slope of glucose potentiation of the insulin response to arginine (102 ± 18.7 vs. 30.2 ± 6.1 pmol/l per mmol/l; P = 0.005) and the maximum insulin response to arginine (2,524 ± 413 vs. 629 ± 159 pmol/l; P = 0.001). Although plasma levels of glucagon-like peptide (GLP)-1 and gastric inhibitory peptide (GIP) did not differ between control and diabetic subjects, the incretin effect was lower in the diabetic patients (70.3 ± 5.4 vs. 52.1 ± 5.9%; P = 0.03). Finally, there was a lack of suppression of glucagon in the patients after both oral and intravenous glucose administration, which may have contributed to their postprandial hyperglycemia. Glucose effectiveness did not differ between patients and control subjects, nor did insulin sensitivity, although there was a tendency for the patients to be insulin resistant (9.18 ± 1.59 vs. 5.22 ± 1.17 pmol · l-1 · min-1; P = 0.08). These data characterize a novel group of subjects with type 1 diabetes manifested solely by hyperglycemia following an oral glucose load in whom islet function is normal at euglycemia, but who have marked defects in both 
- and ß-cell secretion at hyperglycemia. This pattern of abnormalities may be characteristic of islet dysfunction early in the development of type 1 diabetes.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  N. A. Sherry, W. Chen, J. A. Kushner, M. Glandt, Q. Tang, S. Tsai, P. Santamaria, J. A. Bluestone, A.-M. B. Brillantes, and K. C. Herold Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of {beta}-Cells Endocrinology, November 1, 2007; 148(11): 5136 - 5144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bollyky and C. J. Greenbaum The Role of Glucagon in Postprandial Hyperglycemia The Jury's Still Out J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2879 - 2881. [Full Text] [PDF]
|
|
|
|
 |
|
 F. K. Knop, T. Vilsboll, P. V. Hojberg, S. Larsen, S. Madsbad, A. Volund, J. J. Holst, and T. Krarup Reduced Incretin Effect in Type 2 Diabetes: Cause or Consequence of the Diabetic State? Diabetes, August 1, 2007; 56(8): 1951 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gromada, I. Franklin, and C. B. Wollheim {alpha}-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains Endocr. Rev., February 1, 2007; 28(1): 84 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. McKennon and R. K. Campbell The Physiology of Incretin Hormones and the Basis for DPP-4 Inhibitors The Diabetes Educator, January 1, 2007; 33(1): 55 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R K. Campbell Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus Ann. Pharmacother., January 1, 2007; 41(1): 51 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Rickels, A. Naji, and K. L. Teff Insulin Sensitivity, Glucose Effectiveness, and Free Fatty Acid Dynamics after Human Islet Transplantation for Type 1 Diabetes J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2138 - 2144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Takahashi, H. Ishihara, A. Tamura, S. Yamaguchi, T. Yamada, D. Takei, H. Katagiri, H. Endou, and Y. Oka Cell type-specific activation of metabolism reveals that {beta}-cell secretion suppresses glucagon release from {alpha}-cells in rat pancreatic islets Am J Physiol Endocrinol Metab, February 1, 2006; 290(2): E308 - E316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Sherry, E. B. Tsai, and K. C. Herold Natural History of {beta}-Cell Function in Type 1 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S32 - S39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Franklin, J. Gromada, A. Gjinovci, S. Theander, and C. B. Wollheim {beta}-Cell Secretory Products Activate {alpha}-Cell ATP-Dependent Potassium Channels to Inhibit Glucagon Release Diabetes, June 1, 2005; 54(6): 1808 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shao, L. Qiao, R. C. Janssen, M. Pagliassotti, and J. E. Friedman Chronic Hyperglycemia Enhances PEPCK Gene Expression and Hepatocellular Glucose Production Via Elevated Liver Activating Protein/Liver Inhibitory Protein Ratio Diabetes, April 1, 2005; 54(4): 976 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Larger, B. Rakotoaminina, M. Eddouks, J. Timsit, C. Boitard, R. Assan, R. Burcelin, and J.-J. Robert Normal Insulin Sensitivity During the Late Preclinical Stage of Type 1 Diabetes Diabetes Care, July 1, 2004; 27(7): 1842 - 1843. [Full Text] [PDF]
|
|
|
|
|
|
C. Eftychi, J. M.M. Howson, B. J. Barratt, A. Vella, F. Payne, D. J. Smyth, R. C.J. Twells, N. M. Walker, H. E. Rance, E. Tuomilehto-Wolf, et al. Analysis of the Type 2 Diabetes-Associated Single Nucleotide Polymorphisms in the Genes IRS1, KCNJ11, and PPARG2 in Type 1 Diabetes Diabetes, March 1, 2004; 53(3): 870 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Prabhakaran and S. S Anand The metabolic syndrome: an emerging risk state for cardiovascular disease Vascular Medicine, February 1, 2004; 9(1): 55 - 68. [Abstract] [PDF]
|
|
|
|
|
|
N. Pamir, F. C. Lynn, A. M. J. Buchan, J. Ehses, S. A. Hinke, J. A. Pospisilik, K. Miyawaki, Y. Yamada, Y. Seino, C. H. S. McIntosh, et al. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E931 - E939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Suzuki, H. Nakauchi, and H. Taniguchi Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells PNAS, April 29, 2003; 100(9): 5034 - 5039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Federici, A. Petrone, O. Porzio, C. Bizzarri, D. Lauro, R. D'Alfonso, I. Patera, M. Cappa, L. Nistico, M. Baroni, et al. The Gly972->Arg IRS-1 Variant Is Associated With Type 1 Diabetes in Continental Italy Diabetes, March 1, 2003; 52(3): 887 - 890. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |